![ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma](https://www.urotoday.com/images/ASCOGU21_EV-301_2.png)
ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma
![BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy: Molecular Therapy - Nucleic Acids BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/8ada6dfd-5af8-4553-8e97-a8d913330f05/fx1_lrg.jpg)
BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy: Molecular Therapy - Nucleic Acids
![Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology](https://www.thelancet.com/cms/attachment/d9ba62c9-307f-4133-9952-ec5be4f4686b/gr1_lrg.gif)
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial - The Lancet Haematology
![ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma ASCO GU 2021: Primary Results of EV-301: A Phase III Trial of Enfortumab Vedotin Versus Chemotherapy in Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma](https://www.urotoday.com/images/ASCOGU21_EV-301_1.png)